FDA to Review Grail's Multi-Cancer Screening Test in September

Key Facts

In a move reflecting the accelerating pace of innovation in the biotech sector, the U.S. FDA plans to hold a meeting of outside experts in September. The meeting is scheduled to review Grail's Galleri multi-cancer screening test, which is designed to detect various forms of the disease from a single blood draw. This advisory committee session represents a critical milestone in evaluating the test's efficacy and safety for potential regulatory clearance.

According to reports, the announcement of the FDA review triggered a 4% increase in the company's share price, as investors view the formal meeting as a signal of progress toward full commercialization. The evaluation will focus on the technical capabilities of the Galleri test to accurately identify cancer markers, a core element of Grail's growth strategy within the advanced diagnostics market.

Market participants are closely watching the September meeting as a primary catalyst for the firm's regulatory outlook. In the broader economic context, recent U.S. data showed the ISM Manufacturing PMI rising to 55.6 as of August 3, 2026, indicating a robust industrial environment as the healthcare sector awaits these pivotal regulatory decisions.